As the crisis in anti-infective medicine resistance draws closer, the fundamental problems with the existing model for incentivisation of antibiotic research grow ever clearer. Are there issues here with relevance for drug repurposing R&D?
Author Archives: admin
12
Jul
Jul
Numedicus is pleased to announce that its treatment for Rett Syndrome, licensed to AMO Pharma has successfully received Orphan Drug designation. Full details are found here.
26
Jul
Jul
Numedicus is pleased to announce the licensing of two key pieces of intellectual property, and associated know-how, around the use of an existing glutamate modulator, for the treatment of Rett Syndrome and opiate-induced respiratory depression, to AMO Pharma.
18
Jul
Jul
The development of espindolol for the treatment of cancer cachexia entered a new phase this month, with the formation of a new spin out company Actimed Therapeutics.
06
Jun
Jun
The stakeholders in healthcare in the developed world are conventionally divided into three ‘P’ words: patients, payers and pharmaceutical companies. In addition, there are a couple of other more minor players, namely physicians and pharmacists. Recent developments have, however, dramatically increased the importance and changed the role of one of these participants, the patient community.
Uncategorised
Value and cost-based pricing
David Grainger wrote recently on his DrugBaron blog about the pricing of pharmaceuticals. It is an intelligent piece, yet if I may I would like to improve upon it.
Pharmaceutical R&D does not always start with soup and end with nuts, although by analogy this is the classic route followed by what is now the large multinational sector of the industry. A shortcut version of the full programme is followed by generics companies and specialty pharma, who prefer to delay until the entrée is […]